These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32306101)

  • 1. Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib.
    Shankarappa PS; Peer CJ; Odabas A; McCully CL; Garcia RC; Figg WD; Warren KE
    Cancer Chemother Pharmacol; 2020 May; 85(5):1003-1007. PubMed ID: 32306101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
    Lee JH; Chen TW; Hsu CH; Yen YH; Yang JC; Cheng AL; Sasaki SI; Chiu LL; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin CC
    Invest New Drugs; 2020 Feb; 38(1):99-110. PubMed ID: 30825104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.
    Kim A; McCully C; Cruz R; Cole DE; Fox E; Balis FM; Widemann BC
    Invest New Drugs; 2012 Apr; 30(2):524-8. PubMed ID: 21072558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model.
    League-Pascual JC; Lester-McCully CM; Shandilya S; Ronner L; Rodgers L; Cruz R; Peer CJ; Figg WD; Warren KE
    J Neurooncol; 2017 May; 132(3):401-407. PubMed ID: 28290002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
    Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
    Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
    Butowski N; Colman H; De Groot JF; Omuro AM; Nayak L; Wen PY; Cloughesy TF; Marimuthu A; Haidar S; Perry A; Huse J; Phillips J; West BL; Nolop KB; Hsu HH; Ligon KL; Molinaro AM; Prados M
    Neuro Oncol; 2016 Apr; 18(4):557-64. PubMed ID: 26449250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.
    Wesolowski R; Sharma N; Reebel L; Rodal MB; Peck A; West BL; Marimuthu A; Severson P; Karlin DA; Dowlati A; Le MH; Coussens LM; Rugo HS
    Ther Adv Med Oncol; 2019; 11():1758835919854238. PubMed ID: 31258629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
    Voissière A; Gomez-Roca C; Chabaud S; Rodriguez C; Nkodia A; Berthet J; Montane L; Bidaux AS; Treilleux I; Eberst L; Terret C; Korakis I; Garin G; Pérol D; Delord JP; Caux C; Dubois B; Ménétrier-Caux C; Bendriss-Vermare N; Cassier PA
    Sci Transl Med; 2024 Jan; 16(731):eadd1834. PubMed ID: 38266104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas.
    Boal LH; Glod J; Spencer M; Kasai M; Derdak J; Dombi E; Ahlman M; Beury DW; Merchant MS; Persenaire C; Liewehr DJ; Steinberg SM; Widemann BC; Kaplan RN
    Clin Cancer Res; 2020 Dec; 26(23):6112-6121. PubMed ID: 32943455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
    Alsayadi YMMA; Chawla PA
    Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model.
    Omstead AN; Paskewicz M; Gorbunova A; Zheng P; Salvitti MS; Mansoor R; Reed P; Ballengee S; Wagner PL; Jobe BA; Kelly RJ; Zaidi AH
    Carcinogenesis; 2022 Oct; 43(9):842-850. PubMed ID: 35552655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors.
    Yin O; Wagner AJ; Kang J; Knebel W; Zahir H; van de Sande M; Tap WD; Gelderblom H; Healey JH; Shuster D; Stacchiotti S
    J Clin Pharmacol; 2021 Apr; 61(4):480-492. PubMed ID: 33043474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
    Palmerini E; Longhi A; Donati DM; Staals EL
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma.
    Rodgers LT; Lester McCully CM; Odabas A; Cruz R; Peer CJ; Figg WD; Warren KE
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):827-830. PubMed ID: 31894347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.
    Renbarger J; Aleksic A; McGuffey L; Dauser R; Berg S; Blaney S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):39-42. PubMed ID: 14551735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model.
    Cole DE; Lester-McCully CM; Widemann BC; Warren KE
    Cancer Chemother Pharmacol; 2015 May; 75(5):923-8. PubMed ID: 25740692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of chidamide in rat plasma and cerebrospinal fluid.
    Yang H; Li C; Chen Z; Mou H; Gu L
    Regul Toxicol Pharmacol; 2018 Oct; 98():24-30. PubMed ID: 30008379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor.
    Monestime S; Lazaridis D
    Drugs R D; 2020 Sep; 20(3):189-195. PubMed ID: 32617868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the Multi-kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality.
    Zahir H; Greenberg J; Hsu C; Watanabe K; Makino C; He L; LaCreta F
    Clin Pharmacol Drug Dev; 2023 Feb; 12(2):159-167. PubMed ID: 36369799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.
    Ao JY; Zhu XD; Chai ZT; Cai H; Zhang YY; Zhang KZ; Kong LQ; Zhang N; Ye BG; Ma DN; Sun HC
    Mol Cancer Ther; 2017 Aug; 16(8):1544-1554. PubMed ID: 28572167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.